GI Malignancies Debate 2023 - Chicago | Current and future biomarkers for gastroesophageal cancer

Nataliya Uboha, MD, PhD, UW Carbone Cancer Center, Madison, WI, discusses the current standard practice of biomarker testing for patients with gastroesophageal cancer and talks on the identification of new biomarkers which could have an impact on clinical practice in the future. Currently, patients are tested for biomarkers such as microsatellite-instability, HER2 status, and PD-L1 status, but biomarkers such as Claudin18.2 present new opportunities in this field. This interview took place at the Great Debates and Updates GI Malignancies Debate in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.